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Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine 
that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal 
failure and certain cardiovascular pathologies, and in patients with end stage renal 
failure the level of ADMA predicts the risk of cardiovascular events and overall 
mortality. The object of this review is to describe the mechanisms of ADMA 
synthesis, metabolism and uptake and to outline techniques for measuring ADMA and 




Nitric oxide (NO) is a signalling molecule which plays an important role in 
maintaining vascular tone, preventing platelet aggregation [1] and regulating blood 
pressure [2]. Nitric oxide synthases (NOS) produce NO and citrulline from arginine in 
a five-electron oxidation of the guanidine nitrogen of oxygen requiring NADPH and 
tetrahydrobiopterin as cofactors (Figure 1A). Some of the earliest inhibitors of NOS 
were targeted to the arginine binding site and included in this class of guanidine-
substituted arginine analogues was L-NGmonomethylarginine (L-NMMA- Figure 1B; 
Fig 2 [A]) [3,4]. The inhibition constants for L-NMMA have been measured in iNOS, 
nNOS and eNOS to be 6.2µM, 0.18 and 0.94 respectively [5,6,7,8] and the Km for 
arginine ranges from 7-19 µM. There has been speculation about the mechanism of 
NOS inhibition by methylarginines and, at low concentrations of arginine, ADMA 
might bind to elicit uncoupled oxidation of NOS and generate superoxide [9,10]. 
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Several years before the identification of nitric oxide as endothelium dependent 
relaxing factor [11], molecules similar to L-NMMA namely NGNGdimethylarginine 
(ADMA- Fig 1B) and NGNG’dimethylarginine (SDMA- Fig 1B) had been detected in 
urine [12]. In 1992 Vallance et al proposed that the naturally occurring L-NMMA and 
ADMA might regulate nitric oxide production [12, 13]. It was subsequently shown 
that both L-NMMA and ADMA inhibited endothelium dependent contractions of 
aortic rings and altered vascular tone in humans in vivo [12, 13]. ADMA was found to 
inhibit NOS isoforms at equivalent doses as L-NMMA but SDMA did not inhibit 






One of the first proteins observed to have methylated arginine residues was myelin 
basic protein [16]. This process of basic amino acid methylation became well 
documented [17] and it was recognised that arginine methylation occurred shortly 
after protein synthesis. Incorporation of radiolabelled methyl groups onto the arginine 
residues of myelin basic protein revealed that once methylated the reaction appeared 
to be irreversible and the arginine-methylated protein took weeks to degrade [18, 19]. 
Originally methylation was divided into histone and non- histone arginine protein 
methylation. More recent studies have suggested that up to 200 proteins may be 
methylated including proteins involved in translation, transcription, membrane 
transporters, and cell cycle regulation [20].  
Arginine residues on proteins are methylated in vivo by the action of protein arginine 
methyltransferases (PRMT); S-adenosylmethionine (SAM) donates the methyl group 
for the reaction and S-adenosylhomocysteine (SAH) is a reaction by-product. Both 
SAH and SAM affect the rate of arginine methylation, SAM promotes the reaction 
whilst SAH appears to be a weak inhibitor of PRMT activity [21]. 
 
Arginine residues can be asymmetrically methylated by Type 1 PRMTs or 
symmetrically methylated by Type 2 PRMTs; monomethylation of arginine residues 
appears to be an intermediate step in either the Type 1 or Type 2 PRMT reactions. 
Free methylarginines are released as proteins undergo proteolysis (Figure 2 [B]). Type 
1 PRMTs are found in the heart, smooth muscle cells & endothelial cells, at the time 
of writing four Type 1 PRMT isoforms have been identified: PRMT1, PRMT3; 
PRMT4 (CARM1) and PRMT6 (Table 1). PRMT1 is found in brain, liver & testis 
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[22]. PRMT3 is found in adrenal, heart, small intestine, lung, kidney, ovary, testis, 
thyroid, brainstem, cerebellum, cortex, hippocampus and pituitary, with PRMT1 
having a similar pattern of expression but is found at higher levels in lung [23]. 
PRMT3, in contrast to PRMT1, exists as a monomer and is found throughout the 
cytoplasm [23]. The peptide sequences recognised by the Type 1 PRMTs are thought 
to contain arginine flanked by glycine residues [24]. 
PRMT5 is the only known Type2 PRMT and it appears to be localised to the cytosol, 
symmetrically methylated arginine residues have been found in the nucleoplasm of 
HeLa cells [25]. PRMT5, like PRMT3, is sensitive to agents that modify cysteine 
sulphydryl groups [26]. Several single nucleotide polymorphisms (SNP) have been 
identified for the PRMT isoforms and published in the SNP database (Table 1) with 
PRMT3 having significantly more SNP than other isoforms. 
 
The information available about the regulation of PRMT expression and regulation is 
incomplete. Both oxidised and normal low-density lipoprotein (LDL) increase the 
expression of PRMT1, PRMT2 and PRMT3 [27]. Increased activity of PRMT1 has 
been demonstrated following moderate levels of shear stress, which can be attenuated 
by IκB kinase A or the PPARγ activator, troglitazone [28]. The action of shear stress 
upon PRMT1 is attributed to the action of NFγB response element, and following 
shear stress increased levels of methylarginines have been measured [28]. Similar 
levels of shear stress have been shown to activate eNOS through AKT-









Localisation Chromosome SNP Reference 
























 PRMT2 No apparent 
Arginine 
methylation 
Nucleus 21q22.3 87 [33] 
Type 2 PRMT5 MMA, SDMA Cytoplasm 14q11.2 22 [25, 26, 34] 
   
 Table 1: Summary of Type 1 and Type 2 PRMT isoforms, chromosomal localisation as published by 
the Welcome Trust Sanger Centre: http://www.ensembl.org/Homo_sapiens/ and single nucleotide 




ADMA metabolism  
 
A route for ADMA metabolism was proposed following observations in in vivo 
studies that excretion of radiolabelled ADMA and L-NMMA levels were lower than 
those measured in urine for SDMA [35]. An enzyme was identified from rat kidney 
lysate which could metabolise ADMA to citrulline and dimethylamine respectively 
[36]. This enzyme was subsequently purified from rat tissue and became known as 
NG,NG-dimethylarginine dimethylaminohydrolase - DDAH (Figure 2-[C]; [37]); it 
was found later in human tissue [38]. DDAH also metabolises L-NMMA to citrulline 
and methylamine but it has no activity towards SDMA [15]. The activity of DDAH 
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alters the concentration of methylarginines within cells and the levels of NO produced 
by the cells (Figure 2-[A]; [39].  
  
A second DDAH isoform (DDAHII) was identified with 62% homology to DDAHI 
[40]. DDAHII is expressed in highly vascularised tissues and in immune tissues 
whereas the distributions of DDAH1 correlates with those described for nNOS [41]. 
Interestingly DDAHII levels are highly expressed in foetal tissues. Both DDAHI and 
II were found to have a cytosolic localisation suggesting that they maintain low 
ADMA levels throughout the cell [42, 43]. The DDAH1 gene maps to chromosome 
1p22 and DDAHII maps to the MHC III region of chromosome 6p21.3 [41]. 
 
Whilst DDAH plays in important role in metabolising endogenously occurring NOS 
inhibitors, high levels of NO appear to feedback to influence the activity of DDAH. 
Leiper et al demonstrated that DDAH could be nitrosylated [43]. The crystal structure 
showed that the DDAH active site contained a catalytic triad Cys-His-Glu [44] and 
mutation of this active site Cys249 abolished nitrosylation.  Furthermore NO released 
from cytokine stimulated endothelial cells elicited DDAH nitrosylation and reduced 
DDAH activity, indicating that following iNOS induction DDAH activity may be 
reduced leading to an accumulation of methylarginines [43]. It has been suggested 
that zinc might regulate DDAHI activity through interactions with active site cysteine 
residues [45], although no zinc was identified from the crystal structure of DDAH.  
 
Based upon measurements of urinary dimethylamine as an indicator of ADMA 
metabolism, it seems that a healthy adult generates about 300 µM of ADMA per day 
of which 250 µM is metabolised by DDAH [46]. 
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Manipulation of DDAH expression 
 
Treatment of endothelial cells with all-trans-Retinoic acid (atRA) decreases levels of 
secreted ADMA and increases the levels of NOx generated by the cells [47]. DDAHII 
expression is upregulated by all-trans-Retinoic acid, possibly acting through a 
PPAR/RXR site in the DDAHII promoter.  
 
Estrogen also appears to reduce ADMA levels and increase DDAH activity, this 
attenuation in ADMA increased NO levels [48]. In contrast the anti-cancer drug 
tamoxifen increased ADMA levels and reduced levels of NO [48]. Following estrogen 
replacement, in post-menopausal women, levels of plasma ADMA were reported to 
fall, consistent with the observations of estrogen on DDAH activity [49]. 
 
There may also be other factors which regulate DDAH: Interleukin 1β has been 
reported to increase both DDAH and iNOS expression in rat smooth muscle cells with 
a corresponding fall in ADMA levels [50]. ADMA levels were observed to rise in the 
presence of either oxidised LDL or tumour necrosis factor-α, which was accompanied 
by a fall in DDAH activity [51]. DDAHI expression was increased in an in vivo model 
correlating with area of low blood flow in the heart [52], shear stress has been 
demonstrated to effect PRMT activity [28]. 
 
Genetic variants of DDAH 
 
Polymorphisms have now been identified for DDAHII, one of which involves a 
6G/7G variation at -871 of the DDAHII promoter occurring in approximately 1% of 
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the population, this polymorphism tested in promoter reporter assays indicated that it 
might lead to increased basal DDAHII activity [53]. A mutation in human DDAHI 
has also been published [54]. 
At the time of writing there were 13 published single nucleotide polymorphisms 
(SNP) on the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/) for DDAHII 
and 338 reports of SNP for DDAH1. It remains to be seen whether these 
polymorphisms correlate with raised ADMA levels in cardiovascular disorders or can 
be used to predict cardiovascular morbidity. 
 
DDAH regulation of angiogenesis 
 
ADMA has been shown to affect angiogenic processes in an in vivo model [55] and 
atRA, which has been shown to increase DDAH activity [47] has been implicated in 
the regulation of angiogenesis as well as modulating endothelial cell growth and 
differentiation. In DDAHII overexpressing endothelial cells, levels of VEGF were 
increased and there was increased tube formation in an in vitro model [56]. Levels of 
DDAHII are abundant in the placenta, a highly vascularised tissue [40]. DDAH 
overexpression in tumour cells has also been shown to increase VEGF expression and 
leads to increased neovascularisation [57]. 
 
Effects of systemic ADMA 
 
There are numerous reports documenting changes in ADMA levels correlating with 
various cardiovascular disorders. In a randomised double-blinded trial administration 
of ADMA to healthy subjects decreased heart rate, increased cardiac output and 
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caused a rise in blood pressure [46]. Another interesting finding from this study was 
the effect that systemic ADMA had on the vasculature in response to exercise; cardiac 
output doubled in response to exercise, but after ADMA there was a significantly 




The arginine paradox 
Arginine is transported through the cationic amino acid transporters (CAT) of system 
y+, which are sodium independent. In endothelial cells up to 2mM arginine has been 
measured [58] which is significantly higher that the Km for NOS of 7-19 µM [5, 6, 7, 
8], therefore arginine should never be rate limiting for NOS and the NOS enzymes 
should be saturated by substrate arginine. However, in numerous in vitro and in vivo 
studies endothelial NO production has been augmented by arginine supplementation 
(recent review [59]). This has led to unexplained “arginine paradox” where despite 
high intracellular arginine concentrations, arginine can be rate limiting for NOS.  
 
Effects of methylarginines on arginine transport 
 
The methylarginines ADMA, L-NMMA and SDMA have all been shown to compete 
with arginine for the y+ transporter (Figure 2 [D]) and this has been demonstrated in 
macrophages, microvascular and endothelial cells [60; 61; 62]. Some investigators 
have questioned whether the concentrations of ADMA measured in plasma and other 
biological samples for ADMA (typically 0.5 – 1 µM) could inhibit NOS given the 
physiological levels of arginine. The Km of DDAH for ADMA is high (100 uM) and 
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this might suggest that under certain conditions localised ADMA can reach high 
concentrations indeed L-NMMA appears to accumulate greater than 5-fold inside the 
cells [63]. 
Inhibition of DDAH with S-2-amino-4(3-methylguanidino)butanoic acid (4124W) 
leads to a significant accumulation of ADMA [39] culminating in impaired NO 
production [47]. In neurons Zweier & Cardounel reported that intracellular levels of 
ADMA were at levels sufficiently high that more than 50 % of nNOS could be 
expected to be inhibited at any given time [64]. Therefore there is evidence to suggest 
that intracellular levels of ADMA exceed circulating levels and that ADMA may be 
concentrated within cells at levels which can affect NOS. ADMA may also have a 
paracrine action and ADMA secreted from endothelial cells has been demonstrated to 
inhibit the NO production of cytokine stimulated macrophages [65].  
 
Other factors which influence arginine uptake 
 
Arginine uptake is affected the inflammatory stimuli: tumor necrosis factor-alpha 
(TNF-α), interleukin-1 beta (IL-1β), and lipopolysaccharide (LPS). LPS has been 
shown to increase the uptake of L-NMMA by greater than 80% [63; 67] and LPS has 
been shown to increase the expression of CAT mRNA [66]. Arginine transport may 
be influenced by changes in the membrane potential of potassium inward rectifying 
K+ channels.   
The NO signalling pathway appears to directly influence arginine uptake: NO may 
attenuate the uptake of arginine by cells [68], and in response to arginine starvation 
there is an increase in the expression of the cationic amino acid transporter [69]. The 
transport of arginine is altered under pathophysiological conditions. Hypoxia, which 
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is associated with increases in proteolysis, appears to reduce the transport of  arginine 
[70]. During hyperglycaemia there is an increase in the activation of cationic amino 
acid transport which may impact upon diabetes.  
 
 
Methods of detecting ADMA 
  
The original measurements of ADMA were performed using HPLC (Paik 1970; 
Vallance et al 1992) and after 30 years HPLC analysis is the predominant method 
used to determine ADMA levels. In recent years ADMA samples have derivatised by 
ortho-phthaldialdehyde reagent (OPA) and detected by fluorometry which has greatly 
increased the sensitivity of the method (Teerlink et al 2002). Refinements in the 
HPLC techniques and the sample extraction have reduced the amount of starting 
sample, for plasma less than 0.1 ml is required to determine levels of ADMA. 
Limitations of this method for detecting ADMA are the number of samples which can 
be injected and the time required to extract samples prior to HPLC analysis. 
Comparisons of the ratios of ADMA: SDMA and ADMA: arginine have been 
frequently used to describe changes in ADMA in disease states. Typically the levels 
of ADMA in plasma from healthy adults have been described 0.3-1µM (MacAllister 
et al 1996b; Teerlink et al 2002; Zoccali et al 2001) and levels of ADMA in cerebral 
spinal fluid 0.01-0.07 µM (Abe et al 2001; Mulder et al 2002). Interestingly the ratio 
of ADMA to SDMA in CSF is 1:3 whereas in plasma from normal patients there are 
equal levels of ADMA: SDMA (Mulder et al 2002). 
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Several methods have now been described to measure ADMA using mass 
spectrometry coupled to a separation system (Vishwanathan et al 2000; Tsikas et al 
2003,; Martens-Lobenhoffer & Bode-Boger 2003). These methods appear to have 
lowered the limits of detection and may have advantages over HPLC with higher 
sample throughput. Antibodies raised against ADMA are commercially available but 
there are no published reports of groups having successfully used these at the time of 
writing.   
  
Method Basal plasma Limits of 
detection 
Reference 





0.453±0.128µM  0.2 µM Martens-Lobenhoffer 
et al 2003 
Gas 
chromatography 
coupled to MS 
0.39 ± 0.6µMol 10 amol  Tsikas et al 2003 
 Liquid 
chromatography 
coupled to MS-MS 
 25.1+/-9.4 ng/ml  1 ng/ml  Vishwanathan et 
al 2000 
       
 
 
DDAH activity measurement 
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DDAH activity has been measured by the conversion of radiolabelled methylarginine 
to radiolabelled citrulline (MacAllister et al 1996). A colorimetric assay is also in use 
to measure the end point of the DDAH reaction (Knipp et al 2000), citrulline, but is 
limiting for use with coloured assay materials such as particularly tissue. 





ADMA in cardiovascular disorders  
  
It has been recorded over the past 30 years that urinary methylarginines increase in 
various disease states including muscular dystrophy (Lou 1979) and liver disease 
including chronic active hepatitis (Carnegie et al 1977). Changes in ADMA in renal 
failure patients were later associated with impaired NO production (Vallance et al 
1992)  
 
In healthy individuals there appears to be a correlation between levels of ADMA and 
subsequent acute coronary events and the levels of ADMA appear to predict both the 
occurrence of cardiovascular events and mortality (Valkonen et al 2001). In some 
reports ADMA levels are increased in hypertension and high levels of salt in the diet 
might also increase ADMA (Osanai et al 2002). ADMA may contribute to left 
ventricular hypertrophy (Zoccali et al 2002) and reduce renal excretion of sodium 
perhaps contributing to hypertension (Matsuoka et al 1997).  
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Chronic renal failure 
The risk of cardiovascular mortality is increased by 20-fold in association with 
chronic renal failure. In 1992 Vallance et al reported that levels of plasma ADMA 
were several fold higher in renal failure patients than in healthy controls (Vallance et 
al 1992) and that levels of ADMA in these patients were high enough to attenuate the 
production of nitric oxide. In addition to being excreted by the kidneys ADMA is also 
metabolised; DDAH is expressed throughout the kidney and co-localises with NOS 
expression. Changes in ADMA levels are partially associated with impaired renal 
clearance, but in renal failure SDMA and creatinine levels rise concurrently whereas 
there is a smaller increase in ADMA indicating that some ADMA is metabolised by 
DDAH. In a cohort of patients with renal failure, haemodialysis to remove 
methylarginines was found to have an immediate short-term improvement on 
vasodilatation (Cross et al 2001).  
 
In in vivo experiments NOS inhibition, by ADMA or L-NMMA, may be reversed by 
arginine, however the effects of arginine supplementation upon renal failure has been 
tested but conflicting reports have been published regarding the effects (Hand et al 
1998 & Cross et al 2001). 
 
Pulmonary hypertension: 
Pulmonary hypertension is characterised by an increase in pulmonary blood pressure 
accompanied by a fall in NO levels. At birth and for the subsequent 24 hours there is 
increased DDAH activity in lungs correlating with increased NO generation (Arrigoni 
et al 2002). However in a porcine model of persistent pulmonary hypertension, which 
affects the newborn, the hypoxic conditions required to mimic this condition lead to a 
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fall in DDAHII expression and activity (Arrigoni et al 2002). Levels of ADMA have 
been measured in adults with pulmonary hypertension and were found to be 
significantly higher than in control subjects (Gorenflo & Zheng 2001). In another 
animal model of pulmonary hypertension, rats were found to have reduced DDAH 
activity and raised ADMA levels, the pulmonary blood pressure was increased with a 
fall in NO levels despite increased expression of eNOS (Millatt et al 2003). 
 
ADMA as a marker for pre-eclampsia: 
Pre-eclampsia is a disorder of maternal vasculature and effects 3-5 % of pregnancies. 
During the course of normal pregnancy plasma ADMA falls from 0.82 uM to 0.52 uM 
at 24 weeks gestation before gradually rising to the pre-pregnancy levels at term. 
(Fickling et al 1993; Holden et al 1998). This change in circulating ADMA parallels a 
fall in blood pressure and maternal vascular tone to 24 weeks of pregnancy, which 
then increases throughout the rest of the pregnancy. Women who were found to 
develop pre-eclampsia were reported to have ADMA levels greater than 1.45 uM 
(Savvidou et al 2003), subjects who had higher levels of ADMA early in pregnancy 
were most likely to develop pre-eclampsia. Throughout pregnancy high levels of 
protein turnover occur in the uterus, which would be expected to increase the levels of 
methylarginines. In the placenta DDAHII is highly expressed (Leiper et al 1999) 
presumably to metabolise these increased concentrations of ADMA. It has been 
suggested that the raised levels of ADMA associated with pre-eclampsia might reflect 




Levels of S-adenosylhomocysteine (SAH), the end-product in the PRMT methylation 
of arginine residues, are associated with the risk of cardiovascular events. Circulating 
concentrations of ADMA are increased in animals fed on homocysteine rich diet 
(Boger et al 2000) and in humans following methionine loading (Boger et al 2001). 
ADMA levels seem to correlate with increased homocysteine levels and impaired 
arterial relaxation. In patients with hyperhomocysteinmia there may be increased 
oxidation of low density lipoproteins (LDL). In an in vitro model, levels of oxLDL 
appear to increase PRMT activity and downregulate the activity of DDAH, which is 
consistent with the increased ADMA observed in hyperhomocysteinemia. 
Homocysteine has also been proposed to oxidise the cysteine residue of DDAH at the 




The development of atheroma can be assessed by measuring the lumen diameter of a 
vessel, in a cohort of patients with end stage renal failure undergoing hemodialysis, 
ADMA levels were been reported to correlate with intima-media thickness (Zoccali et 
al 2002). In another study of healthy individuals measuring the intimal-medial 
thickness of the carotid artery, ADMA and age were found to be independent 
predictors of lumen occlusion (Miyazaki et al 1999). The risk of developing atheroma 
is significantly increased in patients with end-stage renal disease, 
hyperhomocysteinemia and type II diabetes conditions which also have elevated 
levels of plasma ADMA (Zoccali et al 2002; Stuhlinger et al 2001; Paiva et al 2003). 
Investigators have proposed that ADMA levels may predict the onset of 
atherosclerotic disease although the number and size of studies remain small. 
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Nitric oxide is important in preventing monocyte adhesion, platelet aggregation and 
vascular smooth muscle cell proliferation. The reduced bioavailability of NO is 
thought to contribute to endothelial dysfunction and the early stages of atheroma 
development. It is not known whether the activities of DDAH or PRMT are effected 
during the progression of atherosclerosis although oxLDL, a marker for the 
progression of atheroma, has been demonstrated to increase PRMT activity and 
reduce DDAH activity (Ito et al 1999; Boger et al 2000).  
 
 
ADMA in Type II diabetes 
The plasma concentration of ADMA appears to have a positive correlation with 
insulin resistance (Stuhlinger et al 2002) and is increased in individuals with Type II 
diabetes. Metformin (Asagami et al 2002) and rosiglitazone (Stuhlinger et al 2002) 
have both been demonstrated to reduce the levels of ADMA associated with Type II 
diabetes and it remains to be seen whether these drugs have an effect through 
modulating either DDAH or PRMT activities. It has been reported that glucose may 
downregulate DDAH activity in an in vivo model correlating with a rise in ADMA 
levels and impaired NO production (Lin et al 2002). However the mechanism by 
which glucose is effects the activity of DDAH remains undetermined. 
 
 
ADMA in Alzheimer’s 
There is conflicting evidence surrounding the involvement of DDAH and ADMA 
levels in Alzheimer’s disease. DDAH may be upregulated in the cytoplasm of neurons 
with cytoskeletal pathology (Nakagomi et al 1999) and ADMA was reported to be 
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lower in Alzheimer’s patients compared to control subjects (Abe et al 2001). 
However, further measurements of ADMA levels in CSF have indicated that there are 





ADMA levels are altered in a wide series of pathophysiological states and the 
importance of measuring the circulating levels of ADMA has been demonstrated in 
predicting cardiovascular events. Techniques for measuring ADMA have improved 
over the past 30 years but it would be of great advantage to the field if multiple 
samples could be screened in parallel. We have mentioned the polymorphisms which 
have been identified in DDAH and PRMT isoforms, in the future genotyping might 
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Figure 2 -  
A] ADMA & L-NMMA inhibit nitric oxide synthases.  
B] Arginine residues on proteins are methylated by PRMT with S-
adenosylmethionine acting as a methyl donor, the arginine residues can be either 
mono- or di-methylated. Free L-NMMA, ADMA and SDMA are released as the 
protein undergoes proteolysis  
C] DDAH metabolises ADMA & L-NMMA to citrulline and dimethylamine or 
methylamine respectively. 
D] ADMA, L-NMMA and SDMA may compete with the cationic amino acid y+ 





List of abbreviations: 
ADMA (NG NG dimethylarginine), SDMA (NGNG`–dimethylarginine), L-NMMA (L- NG-
monomethylarginine), SAH (S-adenosylhomocysteine), SAM (S-adenosylmethionine), PRMT (protein 
arginine methyltransferase); DDAH (dimethylarginine dimethylaminohydrolase); NO (nitric oxide); 
NOS (nitric oxide synthase). 
  
